+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
ID06649708

Phase IIIa Study of HX044 to Evaluate Safety and Effectiveness in Adults with Advanced Solid Tumors

Led by Hanx Biopharmaceuticals (Wuhan) Co., Ltd. · Updated on 2025-01-14

100

Participants Needed

3

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating HX044, an investigational drug, in patients with advanced solid tumor malignancies that are refractory or have relapsed after standard therapies, or for which no effective standard treatment exists. This first-in-human Phase IIIa study aims to find the maximum tolerated dose and recommended Phase 2 dose of HX044, while also assessing its initial antitumor activity and safety. The study drug has previously been tested in animals and found to cause minimal side effects. Participants will receive HX044 through a conventional dose-escalation design using 33 cohorts, with doses given every three weeks. Dose escalation depends on the absence of dose-limiting toxicities during a 21-day evaluation period. Subjects may continue treatment until intolerable toxicity, disease progression, withdrawal, death, loss to follow-up, start of new anticancer treatment, or up to 24 months, whichever occurs first. During the study, participants will be monitored for adverse events, dose-limiting toxicities, and responses based on tumor assessments using RECIST 1.1 and iRECIST criteria for about two years. Laboratory tests will evaluate organ function and the presence of anti-drug antibodies at scheduled cycles. Safety and pharmacokinetics will be closely followed to understand how the drug behaves and its tolerability over time.

CONDITIONS

Brief Title

HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies

Research Team

S

Shuang Liu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here